Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Invested Capital (2022 - 2025)

Spyre Therapeutics' Return on Invested Capital history spans 4 years, with the latest figure at 0.35% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 12.0% year-over-year to 0.35%; the TTM value through Dec 2025 reached 0.35%, up 12.0%, while the annual FY2025 figure was 0.33%, 25.0% up from the prior year.
  • Return on Invested Capital reached 0.35% in Q4 2025 per SYRE's latest filing, up from 0.44% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 46.24% in Q2 2023 to a low of 1.88% in Q1 2023.
  • Average Return on Invested Capital over 4 years is 2.85%, with a median of 0.5% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: soared 4744bps in 2023, then plummeted -4682bps in 2024.
  • A 4-year view of Return on Invested Capital shows it stood at 1.44% in 2022, then skyrocketed by 743bps to 9.23% in 2023, then tumbled by -105bps to 0.47% in 2024, then grew by 25bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Return on Invested Capital are 0.35% (Q4 2025), 0.44% (Q3 2025), and 0.41% (Q2 2025).